BRPI0810081A2 - Agente terapêutico e agente diagnóstico para doenças cerebrais de disfunção mitocondrial - Google Patents
Agente terapêutico e agente diagnóstico para doenças cerebrais de disfunção mitocondrialInfo
- Publication number
- BRPI0810081A2 BRPI0810081A2 BRPI0810081-0A2A BRPI0810081A BRPI0810081A2 BR PI0810081 A2 BRPI0810081 A2 BR PI0810081A2 BR PI0810081 A BRPI0810081 A BR PI0810081A BR PI0810081 A2 BRPI0810081 A2 BR PI0810081A2
- Authority
- BR
- Brazil
- Prior art keywords
- agent
- brain diseases
- therapeutic agent
- diagnostic
- diagnostic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007099508A JP5098051B2 (ja) | 2007-04-05 | 2007-04-05 | ミトコンドリア障害脳疾患治療剤及び診断剤 |
| PCT/JP2008/055959 WO2008126693A1 (ja) | 2007-04-05 | 2008-03-27 | ミトコンドリア障害脳疾患治療剤及び診断剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0810081A2 true BRPI0810081A2 (pt) | 2014-10-21 |
Family
ID=39863800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0810081-0A2A BRPI0810081A2 (pt) | 2007-04-05 | 2008-03-27 | Agente terapêutico e agente diagnóstico para doenças cerebrais de disfunção mitocondrial |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20100120916A1 (pt) |
| EP (2) | EP3281642B1 (pt) |
| JP (1) | JP5098051B2 (pt) |
| KR (2) | KR101250576B1 (pt) |
| CN (1) | CN101678047B (pt) |
| AU (1) | AU2008239234B2 (pt) |
| BR (1) | BRPI0810081A2 (pt) |
| CA (1) | CA2682855C (pt) |
| NZ (1) | NZ580138A (pt) |
| RU (1) | RU2435595C2 (pt) |
| WO (1) | WO2008126693A1 (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101322259B1 (ko) * | 2008-10-27 | 2013-10-28 | 에스비아이 파마 가부시키가이샤 | 5-아미노레불린산 혹은 그의 유도체, 또는 그들 염을 유효성분으로 하는 성인병의 예방·개선제 |
| JP5574329B2 (ja) * | 2010-05-06 | 2014-08-20 | 国立大学法人 岡山大学 | ミトコンドリアの蛍光染色方法 |
| JPWO2012067152A1 (ja) * | 2010-11-16 | 2014-05-12 | 三菱化学株式会社 | ＥｎｄｏｔｈｅｌｉａｌＰｒｏｔｅｉｎＣＲｅｃｅｐｔｏｒ蛋白質による脳梗塞の検査方法 |
| JP5713473B2 (ja) * | 2011-06-16 | 2015-05-07 | Ｓｂｉファーマ株式会社 | アレルギー性鼻炎の治療剤 |
| JP5920901B2 (ja) * | 2012-07-19 | 2016-05-18 | Ｓｂｉファーマ株式会社 | インフルエンザウイルス感染症の予防・治療剤 |
| US11633505B2 (en) | 2012-12-11 | 2023-04-25 | National University Corporation Kumamoto University | Nuclear magnetic resonance diagnostic agent, and method for detecting or diagnosing state of cell, tissue or organ in subject using same |
| US20160271090A1 (en) * | 2013-10-29 | 2016-09-22 | Tokyo University Of Agriculture | Frataxin enhancer |
| JP6602651B2 (ja) * | 2015-11-24 | 2019-11-06 | Ｓｂｉファーマ株式会社 | 神経発達障害改善剤 |
| EP3508200B1 (en) * | 2016-09-02 | 2024-04-10 | SBI Pharmaceuticals Co., Ltd. | Aqueous formulation containing 5-aminolevulinic acid or the like |
| KR102007980B1 (ko) * | 2016-11-29 | 2019-08-06 | (주) 위디어 | 신규 유산균을 이용한 퇴행성 뇌질환 예방 및 치료용 조성물 |
| US10590496B2 (en) * | 2016-11-29 | 2020-03-17 | Wedea Inc. | Composition for preventing and treating degenerative brain disease using novel lactic acid bacteria |
| EP3636256B1 (en) | 2017-05-31 | 2024-07-03 | SBI Pharmaceuticals Co., Ltd. | Prophylactic or therapeutic agent for hyperactive bladder |
| WO2018235728A1 (ja) * | 2017-06-23 | 2018-12-27 | Ｓｂｉファーマ株式会社 | 神経障害を改善するための医薬組成物 |
| RU2693627C2 (ru) * | 2017-11-03 | 2019-07-03 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Комбинации эдаравона для лечения ишемических повреждений мозга |
| EP3713563B1 (en) * | 2017-11-22 | 2025-02-19 | Khondrion Ip B.V. | Amide derivatives of chromanyl or chromanyl quinones for use in treating depression and migraine |
| JP6717989B2 (ja) | 2018-02-05 | 2020-07-08 | テラ・ストーン株式会社 | 細胞内でのａｔｐ産生を賦活するための補酵素因子の使用 |
| TWI920402B (zh) | 2018-02-05 | 2026-04-01 | 日商照化學股份有限公司 | 包含去氮黃素并睪固酮化合物或去氮黃素并膽固醇化合物的醫藥組成物 |
| DK3796979T3 (da) * | 2018-04-20 | 2025-07-14 | Fond Telethon Ets | Mir-181-hæmmere og anvendelser deraf |
| CN113260358A (zh) * | 2018-12-20 | 2021-08-13 | 普惠德生技股份有限公司 | 含有亚铁胺基酸螯合物粒子的组合物用于制备治疗或减缓神经受损相关疾病的医药品的用途 |
| RU2744453C2 (ru) * | 2019-09-02 | 2021-03-09 | Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук (ИТЭБ РАН) | Таргетная неинвазивная трансплантация в мозг функционально активных митохондрий для лечения нейродегенеративных заболеваний |
| EP4309651A4 (en) * | 2021-01-25 | 2024-11-06 | Juntendo Educational Foundation | THERAPEUTIC AGENT FOR HYPERTROPHIC CARDIOMYOPATHY |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0331665Y2 (pt) * | 1984-09-05 | 1991-07-04 | ||
| US5079262A (en) | 1989-07-28 | 1992-01-07 | Queen's University At Kingston | Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid |
| JP2767318B2 (ja) | 1990-04-11 | 1998-06-18 | 株式会社コスモ総合研究所 | ５―アミノレブリン酸アルキルエステル又はその塩及びその製造方法並びにこれを有効成分とする除草剤 |
| MX9504023A (es) * | 1994-09-20 | 1997-05-31 | Johnson & Johnson | Composicion farmaceutica y transdermicamente activa que contiene acido 5-aminolaevulinico y procedimiento para su preparacion. |
| DE122006000051I1 (de) | 1995-03-10 | 2007-01-04 | Photocure Asa | Ester der 5-Aminolevulins{ure als Mittel zur Photosensibillisierung in der Chemotherapie |
| GB9701675D0 (en) * | 1997-01-28 | 1997-03-19 | Bridgeman Keith | Composition for the treatment of parkinson's disease |
| JP3644809B2 (ja) * | 1997-10-15 | 2005-05-11 | コスモ石油株式会社 | 頭部用外用剤 |
| WO2005033092A1 (en) * | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| JP4630087B2 (ja) | 2004-03-30 | 2011-02-09 | コスモ石油株式会社 | ５−アミノレブリン酸硝酸塩及びその製造方法 |
| JP4417865B2 (ja) | 2004-03-30 | 2010-02-17 | コスモ石油株式会社 | ５−アミノレブリン酸リン酸塩、その製造方法及びその用途 |
| JP4719483B2 (ja) | 2004-03-30 | 2011-07-06 | コスモ石油株式会社 | ５−アミノレブリン酸スルホン酸塩の製造方法 |
| BRPI0418784B1 (pt) | 2004-04-28 | 2014-08-19 | Cosmo Oil Co Ltd | Composição restauradora de cabelo, e, método não-terapêutico para restaurar cabelo |
| JP5034032B2 (ja) * | 2004-09-29 | 2012-09-26 | Ｓｂｉファーマ株式会社 | 腫瘍診断剤 |
| BRPI0520076B1 (pt) * | 2005-04-28 | 2018-05-08 | Cosmo Oil Co Ltd | preparação externa para pele, drogas preventivas/melhoradoras para aspereza de pele, para pele seca, e para rugas/manchas, métodos para prevenir/melhorar aspereza de pele, pele seca, e rugas/manchas, droga melhoradora de dermatite atópica, método para melhorar dermatite atópica, e, conjunto de preparações externas para pele |
| EP1742038A1 (en) * | 2005-07-06 | 2007-01-10 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Device and method for determining the concentration of a substance |
| ITBO20050596A1 (it) | 2005-10-06 | 2006-01-05 | Gd Spa | Metodo ed unita' per il trasferimento di un prodotto in una macchina impacchettatrice intermittente |
-
2007
- 2007-04-05 JP JP2007099508A patent/JP5098051B2/ja active Active
-
2008
- 2008-03-27 KR KR1020097020513A patent/KR101250576B1/ko active Active
- 2008-03-27 WO PCT/JP2008/055959 patent/WO2008126693A1/ja not_active Ceased
- 2008-03-27 EP EP17193845.9A patent/EP3281642B1/en active Active
- 2008-03-27 CA CA2682855A patent/CA2682855C/en active Active
- 2008-03-27 NZ NZ580138A patent/NZ580138A/en unknown
- 2008-03-27 AU AU2008239234A patent/AU2008239234B2/en active Active
- 2008-03-27 CN CN2008800108818A patent/CN101678047B/zh active Active
- 2008-03-27 BR BRPI0810081-0A2A patent/BRPI0810081A2/pt not_active Application Discontinuation
- 2008-03-27 KR KR1020127034024A patent/KR101383418B1/ko active Active
- 2008-03-27 US US12/594,672 patent/US20100120916A1/en not_active Abandoned
- 2008-03-27 EP EP08739088.6A patent/EP2135613B1/en active Active
- 2008-03-27 RU RU2009136582/15A patent/RU2435595C2/ru active
-
2012
- 2012-09-13 US US13/613,565 patent/US8927532B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100014718A (ko) | 2010-02-10 |
| RU2435595C2 (ru) | 2011-12-10 |
| US20100120916A1 (en) | 2010-05-13 |
| AU2008239234B2 (en) | 2012-11-08 |
| CN101678047B (zh) | 2013-05-22 |
| CA2682855C (en) | 2015-06-23 |
| US20130011337A1 (en) | 2013-01-10 |
| CA2682855A1 (en) | 2008-10-23 |
| EP3281642A1 (en) | 2018-02-14 |
| KR101250576B1 (ko) | 2013-04-03 |
| EP2135613A4 (en) | 2010-07-21 |
| KR20130004943A (ko) | 2013-01-14 |
| AU2008239234A1 (en) | 2008-10-23 |
| EP3281642B1 (en) | 2019-05-01 |
| NZ580138A (en) | 2011-04-29 |
| US8927532B2 (en) | 2015-01-06 |
| JP5098051B2 (ja) | 2012-12-12 |
| EP2135613B1 (en) | 2017-11-22 |
| JP2008255059A (ja) | 2008-10-23 |
| WO2008126693A1 (ja) | 2008-10-23 |
| CN101678047A (zh) | 2010-03-24 |
| RU2009136582A (ru) | 2011-04-10 |
| EP2135613A1 (en) | 2009-12-23 |
| KR101383418B1 (ko) | 2014-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2119444A4 (en) | THERAPEUTIC AGENT FOR PAIN | |
| BRPI0819630A2 (pt) | Montagem de interface de paciente para terapia respiratória | |
| BRPI0908026A2 (pt) | Métodos para o tratamento de doenças do intestino | |
| BRPI0813725A2 (pt) | Métodos e composições para tratamento de doenças | |
| BRPI0919920A2 (pt) | compostos para tratamento de doenças e desordens oftálmicas | |
| BRPI0821660A2 (pt) | Combinações de agentes terapêuticos para tratamento de câncer | |
| EP2166837A4 (en) | DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS | |
| BRPI0819241A2 (pt) | Compostos derivados de amina para o tratamento de distúrbios e doenças oftálmicas | |
| BRPI1012116A2 (pt) | composição farmacêutica para o tratamento de doenças cardíacas | |
| BRPI1006733A2 (pt) | kit para formação de imagem médica marcada e/ou produtos terapêuticos, agente de pré-marcação, sonda de formação de imagem, sonda terapêutica e método | |
| BR112012004166A8 (pt) | colocação otimizada de cânula para aplicação de agentes terapêuticos ao cérebro | |
| PL2442814T3 (pl) | Bifidobacteria do leczenia cukrzycy i pokrewnych chorób | |
| PT2504005E (pt) | Utilização de derivados de 1,3-difenilprop-2-en-1-ona para tratamento de doenças hepáticas | |
| BRPI0821145A2 (pt) | Agente terapêutico para prurido | |
| SI2056842T1 (sl) | Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj | |
| BRPI0816712A2 (pt) | terapia de intervalo para o tratamento de tinnitus | |
| PT3045474T (pt) | Agentes terapêuticos para o tratamento de doenças associadas à proliferação celular indesejada | |
| BRPI0815551A2 (pt) | Tratamento através de hucbc de doença beta-amiloide | |
| ATE530175T1 (de) | Therapeutische kombination für schmerzhafte medizinische zustände | |
| PT2236149E (pt) | Composição medicinal para o tratamento de doenças infeciosas respiratórias | |
| EP2133083A4 (en) | THERAPEUTIC FOR SKIN OR MOLECULE INFECTIONS | |
| EP2135613A4 (en) | MEDICAMENT AND DIAGNOSIS FOR BRAIN DISEASE DUE TO MITOCHONDRIAL DYSFUNCTION | |
| PL1981515T3 (pl) | Leczenie urazów i chorób mózgu za pomocą MAPC | |
| FI20095600L (fi) | Koostumus ihosairauksien hoitoa varten | |
| BRPI0923688A2 (pt) | compostos e métodos para o tratamento de dor e outras doenças |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: SBI PHARMACEUTICALS CO., LTD. (JP) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 33/26 , A61K 31/197 , A61K 49/00 , A61P 9/00 , A61P 9/10 , A61P 21/00 , A61P 25/00 , A61P 25/06 , A61P 25/16 , A61P 25/24 , A61P 25/28 , A61P 43/00 Ipc: A61K 49/00 (1980.01), A61P 21/00 (2000.01), A61P 2 |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |